July 12, 2022 | Pharma, clinical trials, innovative trials, patient recruitment, pharmaceutical
COVID-19 has hugely affected clinical trials and patient recruitment, with the entire industry on hold for some time causing backlogs and delays most of the studies.
In a recent webinar Kate Shaw,Innovative Trials’ Founder & CEO,  Whitney Taynton, Unit Head at Innovative Trials, and Jane Thurston, Senior Patient Recruitment Lead for Parexel, discussed strategies for accelerating patient recruitment in clinical trials post-COVID-19 that will satisfy both sites and sponsors.
Read more here
This content was provided by Innovative Trials
Company Details
Latest Content from Innovative Trials
Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to…
We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient…
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis
Innovative Trials and Parexel invite you to attend the live webinar
The patient recruitment organisation has been shortlisted in the Inspiring Hertfordshire awards
Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.
A key requirement for clinical trials is to understand the effect of potential treatments on the patient populations that will benefit most. Despite this, many studies find diverse patient recruitment…
Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study
In the latest blog post, Innovative Trials’ Equality & Diversity committee focuses on eating disorders
Innovative Trials, Pfizer and Parexel invite you to attend the live webinar
